Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors

Almost No Patients Required Post-Treatment Factor Replacement Therapy

UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.

Hemophilia_525478450_1200.jpg
Freeline announced data from the Phase I/II study of its hemophilia B gene therapy. • Source: Shutterstock

Freeline Therapeutics Holdings PLC is touting data from its Phase I/II clinical trial of FLT180a (vebrinacogene setparvovec) in hemophilia B, showing that virtually none of the patients in the study required Factor IX (FIX) replacement therapy after treatment with the company’s gene therapy.

London-based Freeline plans to move FLT180a into a pivotal Phase IIb/III study, which it will initiate in the second half...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

More from Therapeutic Category